Alkem Laboratories signs licensing agreement with Sonnet BioTherapeutics Holdings

Ace News

10th Oct 2024

Alkem Laboratories has entered into a licensing agreement with US-based Sonnet BioTherapeutics Holdings, Inc (Sonnet) to develop, manufacture and commercialise the drug candidate ‘SON-080’ for the treatment of diabetic peripheral neuropathy in India. ‘SON-080’ is Sonnet’s proprietary version of ‘atexakin alfa’. It has shown encouraging data in phase 1b clinical trial. The drug candidate was demonstrated to be well-tolerated and the pain and quality of life survey results suggested a potential for rapid improvement of peripheral neuropathy symptoms and post-dosing durability, compared to placebo controls.

Under the licensing agreement, the company will carry out the clinical development of ‘SON-080’ in India with support from Sonnet and enable global and India regulatory filings. The company has exclusive rights to develop, manufacture and commercialise the drug in India.

Alkem Laboratories is a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products.